Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
13 evidence topics · 13 sources
Mast cell activation as the central mechanism
“Urticaria is predominantly a mast cell‐driven disease but the triggers that activate mast cells are heterogeneous, diverse, and vary from patient to patient” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the result of mast cell activation is the release of mediators such as histamine and platelet activation factor (PAF), among others, which are responsible for sensory nerve stimuli (pruritus), vasodilatation (erythema), and inflammatory cells chemoattraction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Histologically, wheals are characterized by degranulated mast cells, with edema of the upper‐ and mid‐dermis, with dilatation and augmented permeability of the postcapillary venules as well as lymphatic vessels of the upper dermis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In angioedema, similar changes occur primarily in the lower dermis and the subcutis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Skin mast cells as the primary effector cell, with increased numbers in lesional and non-lesional skin
“This review presents evidence that the skin mast cell, in particular the MCTC subtype, is the primary effector cell in urticaria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Increased numbers of mast cells are found in both lesional and non-lesional skin in CSU and inducible urticaria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Histamine, PGD2 and tryptase are found in the venous blood draining wheal formation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The last 2 are specific for mast cells rather than basophils.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other cells, receptors, and pathways: T cells, B cells, eosinophils, basophils, MRGPRX2, complement, and coagulation
“Other than the histamine receptor, there are other receptors on mast cells that are also involved, such as the Mas‐related G‐protein coupled receptor member X2 (MRGPRX2)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition to mast cells, several other cells and mediators can contribute to the pathology of CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These include T cells (i.e., interaction via OX40/OX40L, T cell cytokines), B cells (autoantibody production), eosinophils (i.e., release of MRGPRX2 agonists), neutrophils or basophils, macrophages, sensory nerves (i.e., release of neuropeptides), and others” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The non‐lesional skin of CSU patients has been shown to exhibit an upregulation of adhesion molecules, infiltrating eosinophils, altered cytokine expression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Also, a significant number of CSU patients show signs of type 2 inflammation‐driven comorbidities” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Autoimmune endotypes: type I (autoallergic) and type IIb autoimmune CSU
“In more than 50% of CSU patients, the pathophysiology is driven by two main autoimmune mechanisms: Type I (autoallergy) involving IgE autoantibodies against autoallergens, and type IIb involving IgG autoantibodies; a subpopulation of patients with CSU has both types” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type I autoallergic CSU: IgE autoantibodies to thyroid peroxidase and other autoantigens
Type IIb autoimmune CSU: 8% meeting all three criteria in a multinational study of 182 participants
“This was a multinational, multicenter study of 182 CSU patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 182 patients, 107 (59%) were ASST+, 46 (25%) were BASO+, and 105 (58%) were IgG anti-FcεRI+/IgE+.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen patients (8%) fulfilled all three criteria of aiCSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“aiCSU patients appeared more severe (UAS7 21 vs 9 P < 0.016) but showed no other clinical or demographic differences from non-aiCSU patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“aiCSU patients also had markedly lower total IgE levels (P < 0.0001) and higher IgG anti-TPO levels (P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of biomarkers, positive BAT and BHRA tests were 69% and 88% predictive of aiCSU, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Type IIb autoimmune CSU: prevalence by number of positive markers
Biomarkers of type IIb autoimmune CSU: low total IgE, elevated IgG-anti-TPO, basopenia, eosinopenia, and basophil tests
“We analyzed records of patients with CSU from 2 independent cohorts (n = 1120) for demographic, clinical, and laboratory parameters and treatment responses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cutoff values were greater than or equal to 34 kU/L (high aTPO) and less than 40 IU/mL (low total IgE).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One of 10 patients with CSU had both high aTPO and low IgE (aTPO↑IgE↓, 11%, n = 123).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Almost half the patients with aTPO↑IgE↓ (44%, 19 of 43) had a positive BAT result, the best single marker for aiCSU, versus 12% (43 of 344) of patients without aTPO↑IgE↓ (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with aTPO↑IgE↓ showed low response rates to antihistamine treatment as compared with patients without aTPO↑IgE↓ (30% vs 47%; P = .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 1,058 records found in the search, 94 studies were reviewed by experts in urticaria and 42 were included in the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In CSU patients, BAT/BHRA+ showed a strong level of evidence for an association with high disease activity and low levels of total IgE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A weak level of evidence was shown for the association of BAT/BHRA+ and the presence of angioedema, and basopenia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Biomarkers in clinical practice: total IgE and IgG-anti-TPO, with limited diagnostic accuracy
“In patients under specialist care, additional tests, such as total IgE and IgG‐anti‐TPO may be performed, as they indicate the likelihood of response to omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the established statistical association, the diagnostic performance and predictive accuracy of these tests remains limited” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, although a clinical association between these laboratory markers and urticaria endotypes has been demonstrated, their clinical usefulness remains limited because there are no studies evaluating their diagnostic accuracy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, cutoff points can be suggested but cannot be recommended for definitive endotype classification” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Validated biomarkers assays are currently under development and are needed to better assist in decision‐making.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KIT and stem cell factor: mast cell dependence on SCF/KIT signaling for survival and maturation
“Mast cells show exceptional dependence on SCF/c-Kit signaling for tissue survival, proliferation, migration, and terminal maturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Loss of function mutations in c-Kit or c-Kitl produce profound tissue mast-cell deficiency, and administration of SCF expands mast-cell populations in vivo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SCF is widely regarded as the main growth factor for mast cells, controlling nearly every stage of mast cell biology, including progenitor differentiation, proliferation of immature and mature cells, survival through inhibition of apoptosis, chemotaxis, adhesion, and effector activation, such as degranulation and cytokine release” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SCF amplifies IgE/FcϵRI-dependent mast cell activation mainly by lowering the activation threshold and enhancing downstream signaling, rather than triggering strong degranulation on its own.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MCs express the tyrosine kinase receptor c-Kit, which binds stem cell factor (SCF), a key regulator of MC differentiation, maturation, proliferation and survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SCF has also been implicated in MC activation, both as a direct trigger of degranulation and as an amplifier” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the reported effects of SCF on MC mediator release are variable with some studies describing comparable levels of mediator release following SCF and anti-IgE stimulation, whereas others report a weaker response to SCF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KIT expression beyond mast cells: melanocytes, hematopoietic progenitors, germ cells, and taste cells
“These include hematopoietic progenitors, melanocytes, germ cells, and mast cells, which all are significantly affected by loss-of-function mutations of KIT or SCF” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many other cells can express KIT constitutively or during immune responses, including dendritic cells, eosinophils, ILC2 cells, and taste cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mast cell depletion through KIT as a therapeutic mechanism
“These include monoclonal antibodies and small molecules that can specifically inhibit mast cell degranulation via key receptors (such as FcεRI), that block specific signal transduction pathways involved in mast cell activation (for example, BTK), that silence mast cells via inhibitory receptors (such as Siglec-8) or that reduce mast cell numbers and prevent their differentiation by acting on the mast/stem cell growth factor receptor KIT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic urticaria (CU) is a mast cell (MC)-dependent disease with limited therapeutic options.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Current management strategies are directed at inhibiting IgE-mediated activation of MCs and antagonizing effects of released mediators.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Current recommended and effective treatment options for urticaria aim to target mast cell mediators at the receptors on nerves and endothelia, mast cell releasability, or mast cell activation by autoimmune triggers among others.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Novel treatments currently under development aim to better regulate Type 2 immunity, or silence mast cells via inhibitory receptors, or to reduce mast cell numbers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gut microbiome: emerging and unresolved role
“There is emerging evidence that changes in the gut microbiome may play a role in the pathophysiology of urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, as with the chicken or the egg dilemma, it is not clear if these changes are the cause or the consequence of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote